¶ Alnylam Pharmaceuticals
.png)
Alnylam Pharmaceuticals is an American biopharmaceutical company based in Cambridge, Massachusetts.
¶ History
Alnylam Pharmaceuticals partnered with Protiva Biotherapeutics to collaboratively develop products using RNAi to inhibit, or “turn off”, target genes (compared to mRNA, which turns on production of proteins), which bore fruit in a 2006 study demonstrating success silencing genes in monkeys.[1]
On March 30, 2008, Protiva announced it was combining its business with Tekmira Pharmaceuticals, reuniting the intellectual property that had become scattered across several startups out of the University of British Columbia (UBC). The new joint company signed a new deal with Alnylam to allow access to their lipid nanoparticle patents - a key component of achieving their self-described “Alnylam 2020” strategy.[2][3]
An agreement was signed on July 27, 2009, mutually establishing the rights and limitations held by Alnylam, UBC, AlCana/Acuitas Therapeutics, Tekmira and Protiva, while explicitly acknowledging the complex nature of the variety of relationships they all had with each other.[4]
¶ Organization
Alnylam is a member of:
- BIOTECanada[5]
- Biotechnology Innovation Organization (BIO)[6]
- National Organization for Rare Disorders (NORD)[7]
- Research!America[8]
Alnylam is partnered with:
- Radcliffe Cardiology[9]
Alnylam has provided notable funding to:
Alnylam is a client of:
¶ Team
| Name | Position | Notes |
|---|---|---|
| Margaret Hamburg | Board member[13] | Food and Drug Administration (FDA), Nuclear Threat Initiative (NTI) |
¶ Investors
Alnylam's investors include:
- Atlas Venture[14]
- Colt Ventures[15]
¶ Activities
Alnylam focuses on the discovery, development and commercialization of RNA interference (RNAi) therapeutics.[16]
¶ External links
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., & Sood, V. (2006). RNAi-mediated gene silencing in non-human primates. Nature, 441(7089), 111–114. https://doi.org/10.1038/nature04688 ↩︎
Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics announce business combination to create new company focused on RNAi delivery and therapeutics. (2008, March 31). Fierce Biotech. https://www.fiercebiotech.com/biotech/tekmira-pharmaceuticals-corporation-and-protiva-biotherapeutics-announce-business ↩︎
Lindenboom, C. R., & Brodsky, J. (2021, January 10). Alnylam launches “Alnylam P5x25” strategy for planned transition to a top five biotech in market capitalization over next five years. Business Wire; Berkshire Hathaway. http://archive.today/2022.03.22-160320/https://www.businesswire.com/news/home/20210110005034/en/Alnylam-Launches-“Alnylam-P5x25”-Strategy-for-Planned-Transition-to-a-Top-Five-Biotech-in-Market-Capitalization-Over-Next-Five-Years ↩︎
Exhibit 10.2. (2009, July 27). Real Deal Docs. https://agreements.realdealdocs.com/Addendum-or-Modifications/Alnylam-Tekmira-Protiva-UBC-AlCa-2894169/ ↩︎
Member Listings. BIOTECanada. Retrieved June 18, 2022, from http://archive.today/2022.06.18-172815/https://www.biotech.ca/about/member-listings/ ↩︎
BIO Member Directory. Biotechnology Innovation Organization. Retrieved September 30, 2022, from https://web.archive.org/web/20220930103715/https://www.bio.org/bio-member-directory ↩︎
Current NORD Corporate Council Members. NORD (National Organization for Rare Disorders). Retrieved October 12, 2022, from https://web.archive.org/web/20221012043656/https://rarediseases.org/get-involved/corporate-council/current-members/ ↩︎
Member Organizations. Research!America. Retrieved April 6, 2022, from http://archive.today/2022.04.06-092643/https://www.researchamerica.org/about-us/member-organizations ↩︎
A-Z. (2022). Radcliffe Cardiology. https://web.archive.org/web/20220612062914/https://www.radcliffecardiology.com/products-services/a-z ↩︎
Annual Report 2019 (p. 23). (2019). Reagan-Udall Foundation. https://web.archive.org/web/20220712071448/https://reaganudall.org/sites/default/files/2022-02/Reagan-Udall_Annual Report 20219_final_corrected.pdf ↩︎
Healthcare Industry Partners and Clients. Figure 1. Retrieved October 7, 2022, from http://archive.today/2022.10.07-071457/https://www.figure1.com/partner-with-us/ ↩︎
Carey, Joanna - Advanced Registry Search Results. Office of the Commissioner of Lobbying of Canada. Retrieved May 16, 2023, from https://web.archive.org/web/20230516210218/https://www.lobbycanada.gc.ca/app/secure/ocl/lrs/do/advSrch?documentType=registration&adv_1001_level1common=&adv_2002_level1reg=lobbyistName&adv_2002_lobbyistName=PETERS&b_adv_2002_lobbyistName=DANIELLE&op_2004=OR&adv_2004_level1reg=responsibleOfficerName&adv_2004_responsibleOfficerName=PETERS&b_adv_2004_responsibleOfficerName=DANIELLE&srch=Search ↩︎
The Alnylam® Leadership Team. Alnylam Pharmaceuticals. Retrieved May 27, 2022, from http://archive.today/2022.05.27-064559/https://www.alnylam.com/about-alnylam/alnylam-leadership ↩︎
Portfolio. Atlas Venture. Retrieved June 18, 2023, from https://web.archive.org/web/20230618173139/https://atlasventure.com/portfolio ↩︎
Portfolio. Colt Ventures. Retrieved December 2, 2022, from https://web.archive.org/web/20221202061953/https://www.coltventures.com/portfolio.php ↩︎
RNAi Therapeutics | How RNA Interference Works. Alnylam® Pharmaceuticals. Retrieved June 2, 2022, from http://archive.today/2022.06.02-233427/https://www.alnylam.com/our-science/the-science-of-rnai ↩︎